Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
Cullinan Therapeutics (Nasdaq: CGEM) announced management participation in two investor conferences and an analyst/investor event at the 2025 ASH Annual Meeting.
CEO Nadim Ahmed and CMO Jeffrey Jones will appear in fireside chats at the Stifel Healthcare Conference in New York on Nov 11, 2025 at 3:20 p.m. ET and at the Guggenheim Healthcare Innovation Conference in Boston on Nov 12, 2025 at 8:00 a.m. ET. The company will host an in-person analyst and institutional investor event on Dec 8, 2025 at 8:00 p.m. ET in Orlando following the oral presentation of Phase 1 CLN-049 results in AML/MDS (Presentation ID 768).
Investors may register by emailing nsmith@cullinantx.com. Webcasts will be available on the company investor relations Events and Presentations page.
Cullinan Therapeutics (Nasdaq: CGEM) ha annunciato la partecipazione della dirigenza a due conferenze per investitori e a un evento analista/investitore al 2025 ASH Annual Meeting.
Il CEO Nadim Ahmed e il CMO Jeffrey Jones parteciperanno a sessioni di tipo fireside chat alla Stifel Healthcare Conference a New York il 11 novembre 2025 alle 15:20 ET e alla Guggenheim Healthcare Innovation Conference a Boston il 12 novembre 2025 alle 8:00 ET. L'azienda organizzerà un evento in presenza per analisti e investitori istituzionali il 8 dicembre 2025 alle 20:00 ET a Orlando, a seguito della presentazione orale dei risultati della Fase 1 CLN-049 in AML/MDS (Presentation ID 768).
Gli investitori possono registrarsi inviando un'email a nsmith@cullinantx.com. Le webcast saranno disponibili sulla pagina Events and Presentations delle relazioni con gli investitori dell'azienda.
Cullinan Therapeutics (Nasdaq: CGEM) anunció la participación de la dirección en dos conferencias para inversionistas y en un evento para analistas/inversionistas en la 2025 ASH Annual Meeting.
El CEO Nadim Ahmed y el CMO Jeffrey Jones participarán en conversaciones informales (fireside chats) en la Stifel Healthcare Conference en Nueva York el 11 de noviembre de 2025 a las 3:20 p.m. ET y en la Guggenheim Healthcare Innovation Conference en Boston el 12 de noviembre de 2025 a las 8:00 a.m. ET. La empresa organizará un evento presencial para analistas e inversionistas institucionales el 8 de diciembre de 2025 a las 8:00 p.m. ET en Orlando, tras la presentación oral de los resultados de la Fase 1 CLN-049 en AML/MDS (ID de Presentación 768).
Los inversionistas pueden registrarse enviando un correo a nsmith@cullinantx.com. Las transmisiones web estarán disponibles en la página de Events and Presentations de relaciones con inversionistas de la empresa.
Cullinan Therapeutics (Nasdaq: CGEM)는 2025 ASH 연례 회의에서 두 차례의 투자자 컨퍼런스 및 분석가/투자자 이벤트에 경영진이 참여한다고 발표했습니다.
CEO Nadim Ahmed와 CMO Jeffrey Jones는 뉴욕에서 열리는 Stifel Healthcare Conference의 2025년 11월 11일 동부 표준시 15:20와 보스턴에서 열리는 Guggenheim Healthcare Innovation Conference의 2025년 11월 12일 동부 표준시 8:00에 fireside chats 형식으로 발표에 참가합니다. 회사는 AML/MDS에서 1상 CLN-049 결과의 구두 발표 후 2025년 12월 8일 동부 표준시 20:00에 올랜도에서 임상의 및 기관 투자자를 위한 대면 이벤트를 개최합니다(발표 ID 768).
투자자 등록은 nsmith@cullinantx.com으로 이메일 주시면 되고 웹캐스트는 회사 IR 페이지의 Events and Presentations에서 이용 가능합니다.
Cullinan Therapeutics (Nasdaq: CGEM) annonce la participation de la direction à deux conférences pour investisseurs et à un événement analystes/investisseurs lors de la 2025 ASH Annual Meeting.
Le PDG Nadim Ahmed et le CMO Jeffrey Jones participeront à des entretiens informels (fireside chats) lors de la Stifel Healthcare Conference à New York le 11 novembre 2025 à 15h20 HE et lors de la Guggenheim Healthcare Innovation Conference à Boston le 12 novembre 2025 à 8h00 HE. La société organisera un événement en personne pour analystes et investisseurs institutionnels le 8 décembre 2025 à 20h00 HE à Orlando, après la présentation orale des résultats de la phase 1 CLN-049 dans AML/MDS (ID de présentation 768).
Les investisseurs peuvent s’inscrire en envoyant un mail à nsmith@cullinantx.com. Les webcasts seront disponibles sur la page Events and Presentations des relations avec les investisseurs de l’entreprise.
Cullinan Therapeutics (Nasdaq: CGEM) gab bekannt, dass die Geschäftsleitung an zwei Investorenkonferenzen und einer Analysten/Investoren-Veranstaltung bei der 2025 ASH Annual Meeting teilnimmt.
CEO Nadim Ahmed und CMO Jeffrey Jones werden an Fireside-Chats bei der Stifel Healthcare Conference in New York am 11. November 2025 um 15:20 Uhr ET sowie bei der Guggenheim Healthcare Innovation Conference in Boston am 12. November 2025 um 8:00 Uhr ET teilnehmen. Das Unternehmen wird am 8. Dezember 2025 um 20:00 Uhr ET in Orlando eine persönliche Veranstaltung für Analysten und institutionelle Investoren ausrichten, nach der mündlichen Präsentation der Ergebnisse der Phase-1-CLN-049 in AML/MDS (Presentation ID 768).
Investoren können sich anmelden, indem sie eine E-Mail an nsmith@cullinantx.com senden. Webcasts werden auf der Seite Events and Presentations der Investor-Relations des Unternehmens verfügbar sein.
Cullinan Therapeutics (Nasdaq: CGEM) أعلنت أن إدارتها ستشارك في عِدَة مؤتمرات للمستثمرين وفي حدث للمحللين/المستثمرين خلال الاجتماع السنوي 2025 ASH.
سينتقل الرئيس التنفيذي نديم أحمد وCMO جيفري جونز إلى جلسات fireside chat في مؤتمر Stifel Healthcare في نيويورك بتاريخ 11 نوفمبر 2025 الساعة 3:20 مساءً بتوقيت شرق الولايات المتحدة وفي مؤتمر Guggenheim Healthcare Innovation في بوسطن بتاريخ 12 نوفمبر 2025 الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة. ستستضيف الشركة حدثاً حضورياً للمحللين والمستثمرين المؤسسات في 8 ديسمبر 2025 الساعة 8:00 مساءً بتوقيت شرق الولايات المتحدة في أورلاندو، بعد العرض الشفهي لنتائج المرحلة 1 CLN-049 في AML/MDS (معرّف العرض 768).
يمكن للمستثمرين التسجيل عبر إرسال بريد إلكتروني إلى nsmith@cullinantx.com. ستتوفر البثوث عبر الويب على صفحة الشركة العلاقات مع المستثمرين Events and Presentations.
- None.
- None.
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune diseases and cancer, today announced its management team will participate in two upcoming investor conferences and will host a company event at the 2025 American Society of Hematology (“ASH”) Annual Meeting in Orlando, FL.
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Healthcare Conference in New York, NY on Tuesday, November 11, 2025, at 3:20 p.m. ET.
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on Wednesday, November 12, 2025, at 8:00 a.m. ET.
- The Company will host an in-person event for analysts and institutional investors on Monday, December 8, at 8:00 p.m. ET, during the 2025 ASH Annual Meeting. The event will follow the oral presentation of results from the Phase 1 study of CLN-049 in patients with AML or MDS earlier that morning (Presentation ID 768). Investors and analysts are invited to register to attend in person by emailing Nick Smith, Head of Investor Relations (nsmith@cullinantx.com).
Webcasts of the fireside chats and the ASH event will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.
Contacts:
Investor Relations
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
FAQ
When will Cullinan Therapeutics (CGEM) present Phase 1 CLN-049 results at ASH 2025?
How can investors attend Cullinan Therapeutics' (CGEM) ASH 2025 analyst event on Dec 8, 2025?
When are Cullinan Therapeutics (CGEM) fireside chats at Stifel and Guggenheim in November 2025?
Will Cullinan Therapeutics (CGEM) webcast its ASH and conference presentations?
Who will represent Cullinan Therapeutics (CGEM) in November 2025 investor events?
